GLP-1 utyalo atholakala: umsizi wamaphila
Uma ukhuluma ngokuthi uhlala kuyinto ozibhalile, Wegovy, Mounjaro, noma Zepbound futhi ufuna ukufumana ukuthi bengakho ngaye — ngaphandle kwezinhlobo ezimbili zemidlalo noma izibhalo ezingafaniyo kwi-Instagram — leliqalo elungile lisho ukubhala abantu abangazibhalile izibonelo ezithile futhi bazame ukukhuluma ngaphandle kokucacisa ukuthi kufuneki ukuyenza nini umzimbe ujikelezi. Asibonakaleli. Kukho kuyinto okuzenzekelayo. Ukuba uyise umngani wakho.
Ngubani iGLP-1 iimpahla, ngokwesibonelo?
Glucagon-like peptide-1 (GLP-1) yintlobo ethunyelwa ngokuchanekile ngokwakho kwiqalaba lapho uqinile. Uyenzeka ngokwamanzo enzalo: ukucaphuna ukuba ipanikreas yakho uyithutha insulini, ukucaphuna ukuba isityalo sakho siqalise ukuswela kwiqalaba lapho siqalisa ukuswela kwiqalaba lapho siqalisa ukuswela kwiqalaba lapho siqalisa ukuswela kwiqalaba lapho siqalisa ukuswela kwiqalaba lapho siqalisa ukuswela kwiqalaba lapho siqalisa ukuswela kwiqalaba lapho siqalisa ukuswela kwiqalaba lapho siqalisa ukuswela kwiqalaba lapho siqalisa ukuswela kwiqalaba lapho siqalisa ukuswela kwiqalaba lapho siqalisa ukuswela kwiqalaba lapho siqalisa ukuswela kwiqalaba lapho siqalisa ukuswela kwiqalaba lapho siqalisa ukuswela kwiqalaba lapho siqalisa ukuswela kwiqalaba lapho siqalisa ukuswela kwiqalaba lapho siqalisa ukuswela kwiqalaba lapho siqalisa ukuswela kwiqalaba lapho siqalisa ukuswela kwiqalaba lapho siqalisa ukuswela kwiqalaba lapho siqalisa ukuswela kwiqalaba lapho siqalisa ukuswela kwiqalaba lapho siqalisa ukuswela kwiqalaba lapho siqalisa ukuswela kwiqalaba lapho siqalisa ukuswela kwiqalaba lapho siqalisa ukuswela kwiqalaba lapho siqalisa ukuswela kwiqalaba lapho siqalisa ukuswela kwiqalaba lapho siqalisa ukuswela kwiqalaba lapho siqalisa ukuswela kwiqalaba lapho siqalisa ukuswela kwiqalaba lapho siqalisa ukuswela kwiqalaba lapho siqalisa ukuswela kwiqalaba lapho siqalisa ukuswela kwiqalaba lapho siqalisa ukuswela kwiqalaba lapho siqalisa ukuswela kwiqalaba lapho siqalisa ukuswela kwiqalaba lapho siqalisa ukuswela kwiqalaba lapho siqalisa ukuswela kwiqalaba lapho siqalisa ukuswela kwiqalaba lapho siqalisa ukuswela kwiqalaba lapho siqalisa ukuswela kwiqalaba lapho siqalisa ukuswela kwiqalaba lapho siqalisa ukuswela kwiqalaba lapho siqalisa ukuswela kwiqalaba lapho siqalisa ukuswela kwiqalaba lapho siqalisa ukuswela kwiqalaba lapho siqalisa ukuswela kwiqalaba lapho siqalisa ukuswela kwiqalaba lapho siqalisa ukuswela kwiqalaba lapho siqalisa ukuswela kwiqalaba lapho siqalisa ukuswela kwiqalaba lapho siqalisa ukuswela kwiqalaba lapho siqalisa ukuswela kwiqalaba lapho siqalisa ukuswela kwiqalaba lapho siqalisa ukuswela kwiqalaba lapho siqalisa ukuswela kwiqalaba lapho siqalisa ukuswela kwiqalaba lapho siqalisa ukuswela kwiqalaba lapho siqalisa ukuswela kwiqalaba lapho siqalisa ukuswela kwiqalaba lapho siqalisa ukuswela kwiqalaba lapho siqalisa ukuswela kwiqalaba lapho siqalisa ukuswela kwiqalaba lapho siqalisa ukuswela kwiqalaba lapho siqalisa ukuswela kwiqalaba lapho siqalisa ukuswela kwiqalaba lapho siqalisa ukuswela kwiqalaba lapho siqalisa ukuswela kwiqalaba lapho siqalisa ukuswela kwiqalaba lapho siqalisa ukuswela kwiqalaba lapho siqalisa ukuswela kwiqalaba lapho siqalisa ukuswela kwiqalaba lapho siqalisa ukuswela kwiqalaba lapho siqalisa ukuswela kwiqalaba lapho siqalisa ukuswela kwiqalaba lapho siqalisa ukuswela kwiqalaba lapho siqalisa ukuswela kwiqalaba lapho siqalisa ukuswela kwiqalaba lapho siqalisa ukuswela kwiqalaba lapho siqalisa ukuswela kwiqalaba lapho siqalisa ukuswela kwiqalaba lapho siqalisa ukuswela kwiqalaba lapho siqalisa ukuswela kwiqalaba lapho siqalisa ukuswela kwiqalaba lapho siqalisa ukuswela kwiqalaba lapho siqalisa ukuswela kwiqalaba lapho siqalisa ukuswela kwiqalaba lapho siqalisa ukuswela kwiqalaba lapho siqalisa ukuswela kwiqalaba lapho siqalisa ukuswela kwiqalaba lapho siqalisa ukuswela kwiqalaba lapho siqalisa ukuswela kwiqalaba lapho siqalisa ukuswela kwiqalaba lapho siqalisa ukuswela kwiqalaba lapho siqalisa ukuswela kwiqalaba lapho siqalisa ukuswela kwiqalaba lapho siqalisa ukuswela kwiqalaba lapho siqalisa ukuswela kwiqalaba lapho siqalisa ukuswela kwiqalaba lapho siqalisa ukuswela kwiqalaba lapho siqalisa ukuswela kwiqalaba lapho siqalisa ukuswela kwiqalaba lapho siqalisa ukuswela kwiqalaba lapho siqalisa ukuswela kwiqalaba lapho siqalisa ukuswela kwiqalaba lapho siqalisa ukuswela kwiqalaba lapho siqalisa ukuswela kwiqalaba lapho siqalisa ukuswela kwiqalaba lapho siqalisa ukuswela kwiqalaba lapho siqalisa ukuswela kwiqalaba lapho siqalisa ukuswela kwiqalaba lapho siqalisa ukuswela kwiqalaba lapho siqalisa ukuswela kwiqalaba lapho siqalisa ukuswela kwiqalaba lapho siqalisa ukuswela kwiqalaba lapho siqalisa ukuswela kwiqalaba lapho siqalisa ukuswela kwiqalaba lapho siqal
Isiko lisetshenziswa:
- Semaglutide — bengesetshenziswa njengOzempic (ukubonakala kwesi-diabetes), Wegovy (ukubonakala kwesibhakabhaka) kunye noRybelsus (umehluko onegunya). Yomolekule yo-yinhlobo yokuqala yokuthuthuka kuyo.
- Tirzepatide — bexwayile njengokuthi Mounjaro kunye no Zepbound. "Dual agonist" ekhuluma ne GLP-1 kunye ne GIP receptors. Kwi trials ezimbini ezinikezile, kubonakala imininingwane yokuqondisa umzekelo engaphezulu kusukela semaglutide.
- Liraglutide — bengesha Victoza kunye no Saxenda. Isibonelo esiqhele, ukutya ngomhla nangaphezulu kwezi zonke.
- Dulaglutide — bethungelwa njengoko Trulicity. Kwindawo yokuba kukho kubalulekileyo.
- Retatrutide — in Phase 3 trials. A triple agonist (GLP-1 + GIP + glucagon). Early data suggests even bigger weight loss than tirzepatide.
Yinto eyenzeka kwiinkcukacha
Oku kuhle — oku kubhedlele, kukhulunywa ngokuchazwa, kukhulunywa ngabanye abantu
- Ukuqhubeka: 15–20% yomibili yomzimba ngaphandle kokugqibela kwi-12–18 iimesi ngemvume. I-trial ezilungile zibe STEP-1 (semaglutide, NEJM 2021) ne SURMOUNT-1 (tirzepatide, NEJM 2022). Kukhona kuyinto engaziyintlobo yee-sample ezinkulu yokugqibela; yizibalo ezinokubonwa ezinokubonwe ezinokubonwe ezinokubonwe ezinokubonwe ezinokubonwe ezinokubonwe ezinokubonwe ezinokubonwe ezinokubonwe.
- HbA1c ukuhlola kwi-type 2 diabetes: ngokuchanekile 1–2% absolute reduction. Lokhu kuchaza, futhi kuchaza izibonelo ezilimi empilweni.
- Imbuzo yomngqalothu: isibonelo soSELECT (semaglutide, Lincoff et al., NEJM 2023) sezazi ukuba kukho ukususa kwezinye ilimi emva kwezinto ezimbili ezifana nezinto zoluntu ezizenzekileyo ezinamandla kumalayini abantu abangafumene ukudala okanye abangafuna ukudala futhi abangayi noma abangayi ngokwesibonelo somngqalothu.
- Kidney protection: FLOW trial showed semaglutide slowed kidney disease progression in type 2 diabetes.
- Ukuphambana kwezalathisi: SURMOUNT-OSA ukubonisa ukuthi tirzepatide kuyakhupha ukuphambana kwezalathisi-uhypopnoea.
- Isidlotho somzimbe: ukuphuzwa kwezilondlole zombhalo wemashonisa (MASH) ezaphambili kwezilondlole zemashonisa (NASH) ezintekwana yase semaglutide.
Lezi zibophezulu zingqalene kunjalo. Akukho simi ukukhathazeka kazo, futhi akukho simi esitye.
Amagcinelo — bona ngokwazi lapha
Lezi zikhundla zoluntu zingafuneki: zibiza isitokiso esisodwa njengomntu waba njengokuthi yinto ethile. Siqhubeka simfanelo yokuba yinto eyenzeka.
Alzheimer's disease. Zibe zibini ezingqalene kwezalathisi zasePhase 3 (EVOKE ne-EVOKE+, Cummings et al., The Lancet, January 2026) bazetesta ukusebenzisa semaglutide yensimbi yomkhuhlane ku-3,800+ abantu abangafumene Alzheimer's ezingqalene. Ngomhla ka-104 kukhona okungaba kwaye akukho ukuphambana kuyakho kwiimfuno zokubhala (CDR-SB) noma iactivities of daily living phakathi kwe-semaglutide ne-placebo. Novo Nordisk wathengisa izalathisi zakhe ze-Alzheimer's ngo-November 2025. Ezinye iibhaimakha yenzeka kwindawo yokukhula (~10% reduction in CSF p-tau181), kodwa akukho isigna sokusebenzisa. Isibonelo esihle: izinhlobo ezinkulu azibhekene.
Ukutshoniswa kweParkinson. Yedwesihlale. I-triali ye-Exenatide-PD3 ye-Phase 3 (UK, 194 abantu, 96 iweki) ithola — akukho okuphathelene kwezalathisi zoluntu, izalathisi ezahlukeneyo, noma ukuqondiswa kwezandla. I-triali ye-LIRA-PD ye-liraglutide yenzeka isimo esincinci, esikuncinci. Ngokwesobukhulu, i-LixiPark (lixisenatide, Phase 2, 156 abantu, NEJM 2024) yenzeka isimo esihle kwezalathisi zoluntu: i-placebo yahamba ngokukhululeka ngamalitha 3.04 kwe-MDS-UPDRS ngaphandle kolixo yaliqondiwe ukhululeka ngokumalitha −0.04 (p=0.007). I-triali ehlukene ye-Phase 2 ekhuluma ne-triali eyenzekile ye-Phase 3 ayikwazi ukukhulunywa njengokwesobukhulu. Ngokwesobukhulu, izinncinci ezi-GLP-1 zishumayelwa kuzokufuneka kubonakala kwi-triali ekugcineneyo.
Ukufa, ukusenzilweni, PCOS, ukugcinenisa ukusibhobho. Iingxelo ezinkulu ezinkulu, iingxelo zoluntu eziningi, ukuphikisana kakhulu ekhuluma ne-phase 3. Ukusebenzisa ngokuchanekileyo.
Isisebenziso somkhuhlane neengxelo — ulwazi oluphele
| Risk | Frequency | Notes |
|---|---|---|
| Nausea, vomiting, diarrhoea | 30–50% in first three months | Usually mild; often fades with dose titration. |
| Pancreatitis | ~1% | Serious — requires medical attention immediately. |
| Gallbladder disease | ~5% | Sometimes needs surgery. |
| Thyroid C-cell tumours | Boxed warning | Avoid if you have a personal or family history of MEN-2 syndrome. |
| Diabetic retinopathy worsening | Uncommon | Monitor in diabetic patients. |
| Muscle loss | 15–40% of weight lost may be lean mass | Mitigable — see our companion piece on avoiding muscle loss. |
| Weight regain after stopping | Up to 2/3 within a year | Almost exclusively fat. Mitigable with diet + exercise transition. |
| Bone density loss | Emerging concern | Monitor in older patients. |
Amagwarha amalungile — isibonelo sokuchaza umsindo wophandle kwesetyalo
U-FDA uqaphamile isikhumba sokuqala se-Ozempic esiyisuka kwi-December 2025 (loti PAR1229), esetshenziswa ngaphandle kwezikhundla zokuthuthuka ezinethunyelwe kwe-Novo Nordisk. U-FBI ubhale izaziso zokuthula ngokuchaza umbuzo wokuqala we-semaglutide ku-2025. "Usemaglutide" oluchazwa kwaye utirzepatide okhulumayo kwezikhundla ezahlukeneyo zapharamasi, kusetyenziswa kuka-testi, kubonakala eziningi, ezindawo ezincinci, okanye akukho umshwana omkhulu othi. U-FDA ubhala (izaziso zombuzo zokuba kwi-June 2026) ukuphinda ukucabanga ngokuchaza umbuzo lwe-503B ukusebenzisa izifo eziyizinhlobo lezi.
KwiiNingizimu Afrika, SAHPRA ayaxolisa (ngomhla kaMayelana 2026) izaziso zokungqalene njengokuba zibonakala kakhulu njengesFDA, koko kubonakala ukukhathazeka. Uma ufuna ukusetyenziswa kwe-GLP-1 umqondiso: bona umngani othunyelwe, bheka umnikazi, ukuze ufake kwi-pharmacy ethunyelwe. i-Online "compounded semaglutide" ekhuluma nezalathisi ezinkulu ezazi zokwazi kuyenzeka izalathisi nezokufa ngaphandle kwezwe lomhlaba. Lokhu kuyinto yokuqala kunye nekugcwele okunokuthembeka singafuna ukukubonisa.
Ubude bethi diet ubukhuluma
Ukuphinda kwezinto ezinzima kwi-litshathiso lwe-2024–2026 lwe-ukuswana kuka-obesity yinto yokuba izinwele zase-GLP-1 zibonisa kakhulu njengama-catalysts ngasemva kwisimo sokuzalukana kabanzi, akaba njengama-replacement yoku. Izinto ezintathu zibonisa ukuba zibonise:
- Ukuphakamisa ikhaphu. Isitshwalamende esinamandla (1.2–1.6 g yee-proteini phakathi kwemidibaniso yombuzo yenshwe yomntu ngomhla) esikhundleni nesikhundla sokuphinda ukuphinda ukuphinda ikhaphu kakhulu ngokukhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakhulu kakh
- Ukuhola kuminyaka ngokugcina. Abantu ababangela isitayela sibonelo simi simi sibonakala simi simi ngokusebenzisa umsebenzi watholakala kuyabonakala nokuhola kabanzi. Abantu abathokozisa ukuthi umsebenzi watholakala yisitayela "sithuthi esihle" futhi athanda ukuzenzela kuyabonakala kuyabonakala ngokugcina.
- Isiselelezo sokuqala kwe-GLP-1. Ifayirhi + iphathegi ngqo zingamalungelo izindlela zasezantsi zokusebenzisa izifo zokusebenzisa izifo — ngamagunya eentshukwane, kodwa ezibonakalayo. Kwezalukazi ezayingafuni ukufikelela nokuqondiswa kwezifo, isisekelo sokuqala somngani yinto yenzeka.
Uthetho lwethu: iGLP-1 imininingwane yee-tools; ukutya kuyinkqubo ethunyelwa yee-tools ezithile. Siyazi sithetho esithi ukutya njengoba ungathembekile ne-Ozempic — ngaphandle kwe-drug, kunye nothetho efanayo ukukhuluma ukuthi ukhuluma ukuphela kumadwala emzimbeni.
Ngakho-ke kufuneka uqaphelise umthombo wa GLP-1?
Yintoni yinto engazazi ukuphendula — yinto yengomngani wakho ophendulayo. Yinto ethunyelwa:
- Uma kubalulekile ukuthi uhlala ekhululekile ngokuchaza kahle izinto zangempela ezithile, i-drug zase-GLP-1 zibe nangaphambili okuyenzeka njengesi-empela okusebenzisa kuzo zombili, okuyenzeka ukuthi umngeni wakho wokuchaza kahle uqhubeka nabo.
- Uma ukhuluma ukuthi ungenxa yemfumpumano (BMI ≥ 30, okanye ≥ 27 nezinto ezinceda), i-drug zase-GLP-1 zibonakala njengomthombo wokusebenzisa ukukhuluma nokutya ukuthi uzobonisa ngomngani wakho wokugqila — ngaphandle kwalaba, kwaye kusukela kwalaba, kubalulekile ukuphatha isitayela.
- Uma ungene ukuxoxa nabo ngokusebenzisa kubalulekile ezinxulumene njengokuchaza umbhokisi okukhululekile ngaphandle kokusebenzisa okukhuluma, fumene ukufumene: umqondo wamagunya oshayiwe kuyinto engazenzekelayo, okuphelele kuyinto engamkelwa, ukukhuluma kuyinto othembekile, kunye nokucaciswa kwezindlela ezinkulu zokuchaza umbhokisi ziyafumaneka. Ukubhala iscripthi ngomntu wasezifo zonke kuyinto engaxolisa njengokubhala iscripthi ngokusebenzisa iziko laba zokusebenzisa ezithile.
- Uma ungaxolisa ukuba uqhamuka noma uhlalelwa kwisezantsi semaglutide ngoba kukhala kuye kuchele: akaxolise. Ukukhathazeka kwezinye izinto ezifanayo kukho kwaye abantu bathi bafuna.